SciCombinator

Discover the most talked about and latest scientific content & concepts.

VY Reddy, DN Gibson, S Kar, W O'Neill, SK Doshi, RP Horton, M Buchbinder, NT Gordon and DR Holmes
Abstract
Left atrial appendage closure (LAAC) using the Watchman device was FDA-approved as a stroke prevention alternative to warfarin for patients with non-valvular atrial fibrillation. However, clinical decision-making is confounded by the fact that while LAAC avoids the anticoagulant-related lifetime risk of bleeding, implantation is associated with up-front complications. Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced beyond the clinical trial sites into general clinical practice.
Tweets*
52
Facebook likes*
9
Reddit*
0
News coverage*
69
Blogs*
1
SC clicks
0
Concepts
Atrial flutter, Clinical trial protocol, Warfarin, Stroke, Clinical trial, Left atrial appendage occlusion, Left atrial appendage, Atrial fibrillation
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com